THE TOTAL SYNTHESIS OF SPERGUALIN, AN ANTITUMOR ANTIBIOTIC
Sir: During our studies of antitumor antibiotics, spergualin was discovered in culture filtrates of a Bacillus strain.') Spergualin showed a marked inhibition against experimental mouse tumors, and the structure was determined to be (-)-(I 5S)-1-amino-l9-guanidino-11,15-dihydroxy-4, 9,12-triazanonadecane-10,13-dione2>. In thiscommunication, we report the synthesis of epimeric spergualin (1) and epimeric (15R)-spergualin (2) , and separation of 1 into natural (-)-spergualin (la) and unnatural (+)-spergualin (1b).* The total synthesis of 1 has been accomplished by acid-catalyzed condensation of (S)-7-guanidino-3-hydroxyheptanamide (3) and 11-amino-l,1-dihydroxy-3,8-diazaundecan-2-one (4, a hydrate of glyoxylylspermidine).
By homologation of L-lysine according to the ARNDT-EJSTERT method'), (S)-3,7-diaminoheptanoic acid (9, colorless syrup, [a],' +29' (c 1, water) 27% yield) was obtained through compounds 5. 8 (Scheme 1). The selective w-amino protection') of 9 with an equimolar amount of N-benzyloxycarbonyloxysuccinimide in a mixture of pyridine, water arid triethylamine (10: 10: 1) at room temperature for 5 hours gave (S)-3-amino-7-benzyloxycarbonylaminoheptanoic acid (10, mp 143-147°C, MY +14' (c 1, methanol), 48% yield). In this step, unreacted 9 was recovered in 24 % yield by column chromatography on Amberlite CG-50 (80%. NH,+). Deamination of 10 with sodium nitrite in 33% aqueous acetic acid overnight at 5°C followed by silica gel (Wakogel C-200) column chromatography (chloroformmethanol -28 % ammonia, 30: 10: 1) afforded (S) -7 -benzyloxycarbonylamino -3 -hydroxyheptanoic acid (11, mp 115-117°C, [a]21d-3' (c 2, methanol), 17% yield) with retention of configuration. It was identical with the compound derived from natural spergualin. Esterification of 11 with diazomethane in 1,2-dimethoxyethane followed by amidation with anhydrous ammonia in methanol at room temperature for 3 days in a sealed tube gave (S)-7-benzyloxycarbonylamino-3-hydroxyheptanamide (12, mp 126'-127°C, [a];,= -3° (c 5 , methanol), 85% yield). Hydrogenolysis of 12 with 5 % palladium on carbon in a mixture of methanol, water and acetic acid (9: 1: 0.01) followed by column chromatography on Dowex 50W-x4 (H+) resin eluted with 0.5 m ammonia afforded (S)-7-amino-3-hydroxyheptanamide (13, Nn-2' (c 2, water), 96Y. yield). Treatment of 13 with an equimolar amount of 2-methyl-l-nitrosourea°) and sodium hydroxide in methanol at 5°C for 5.5 hours followed by hydrogenolysis with 5 % palladium on carbon in a mixture of methanol, water and acetic acid (2: 2: 1) for 1 hour yielded the hydrochloride of 3 ( By high-performance liquid chromatography (HPLC) (Waters Associates, 6000A/UK6) on Nttcleosil 5C1a (Macherey-Nagel, Germany) column (8 x300 mm) eluted with a mixture of (NH4)H.,PO4 (1.16 g), PIC B-5 low UV (Waters Associates, 20 ml), methanol (150 ml) and water (850 ml) at a flow rate of 3 ml/minute, detected by absorption at 205 nm (spectrophotometric detector SPD-l, Shimadzu), the epimeric mixture (1) was separated into natural O-spergualin (1a) and unnatural (+)-spergualin (lb) in retention time at 16.9 and 16.0 minutes, respectively. By purification of each fraction on Sephadex LH-20 column, la trihydrochloride which was identical with the natural one in all respects including optical rotation and antimicrobial activity'', and lb trihydrochloride, [aL/ 7.5° (c 0.2, water), containing 14% of la were obtained. The latter showed 31 % activity of la by ordinary cylinder plate method using Bacillus subtilis PCI219 as the test organism.
Acid-catalyzed condensation of 4 with (R)-7-guanidino-3-hydroxyheptanamide,
[a];,~ -;-2° (c 2, water), which was synthesized starting from Dlysine by the same procedure as in the synthesis of 3 afforded (15R)-spergualin (2) trihydrochloride, no definite nip, [nli,'+1° (c 2, water). The trihydrochloride showed 19°o activity of la against Bacillus subtilis PC1219 and only weak antitumor activity against leukemia L-1210 in mice.
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